725 | CONVENTIONAL CHEMOTHERAPY REMAINS EFFECTIVE IN RELAPSED AND PRIMARY REFRACTORY CLASSICAL HODGKIN LYMPHOMA IN THE ERA OF NOVEL AGENTS: A SINGLE‐INSTITUTION EXPERIENCE

Documenti analoghi

• 828 | TRIAL IN PROGRESS: PEMBROLIZUMAB IN COMBINATION WITH SALVAGE CHEMOTHERAPY FOR FIRST‐RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (PEMBRO‐CORE)
  di: H. Tharmaseelan, et al.
  Pubblicazione: (2025)
• 361 | REAL‐WORLD OUTCOMES OF PATIENT WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA TREATED WITH BRENTUXIMAB‐VEDOTIN IN ASSOCIATION WITH BENDAMUSTINE: THE FRENCH LYSA EXPERIENCE
  di: G. Basile, et al.
  Pubblicazione: (2025)
• 362 | BRENTUXIMAB VEDOTIN‐ICE AS SALVAGE TREATMENT PRIOR TO STEM CELL TRANSPLANT IN REFRACTORY AND RELAPSED HODGKIN LYMPHOMA PATIENTS. A MULTICENTER REAL‐WORLD EXPERIENCE
  di: P. Dutari, et al.
  Pubblicazione: (2025)
• 341 | IBRUTINIB FOR THE TREATMENT OF RELAPSED/REFRACTORY PRIMARY OR SECONDARY CENTRAL NERVOUS SYSTEM LARGE B‐CELL LYMPHOMAS: EXPERIENCE FROM THE GELTAMO GROUP
  di: D. Alonso Castronuño, et al.
  Pubblicazione: (2025)
• 130 | TISLELIZUMAB, AN ANTI‐PD‐1 ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: FINAL ANALYSIS FROM THE LYSA PHASE 2 TIRHOL STUDY BGB‐A317‐210
  di: H. Ghesquières, et al.
  Pubblicazione: (2025)